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Long non-coding RNAs (lncRNAs) are important regulatory molecules that are implicated in
cellular physiology and pathology. In this work, we dissect the functional role of the HOXB-
AS3 lncRNA in patients with NPM1-mutated (NPM1mut) acute myeloid leukemia (AML). We
show that HOXB-AS3 regulates the proliferative capacity of NPM1mut AML blasts in vitro and
in vivo. HOXB-AS3 is shown to interact with the ErbB3-binding protein 1 (EBP1) and guide
EBP1 to the ribosomal DNA locus. Via this mechanism, HOXB-AS3 regulates ribosomal RNA
transcription and de novo protein synthesis. We propose that in the context of NPM1
mutations, HOXB-AS3 overexpression acts as a compensatory mechanism, which allows
adequate protein production in leukemic blasts.
https://doi.org/10.1038/s41467-019-13259-2 OPEN
1 The Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA. 2 Center for RNA Medicine, Department of Clinical Medicine, Aalborg
University, Copenhagen, Denmark. 3Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK. 4 Institute of Genetics and
Biophysics (IGB-ABT), National Council of Research (CNR), Naples, Italy. 5 Department of Pathology, New York University School of Medicine, New York,
NY, USA. 6 Department of Molecular Genetics, Center for RNA Biology, The Ohio State University, Columbus, OH, USA. 7 Alliance for Clinical Trials in
Oncology Statistics and Data Center, The Ohio State University, Columbus, OH, USA. 8Department of Cancer Biology and Genetics, The Ohio State
University, Columbus, OH, USA. 9 Department of Molecular Medicine, University of Pavia, Pavia, USA. 10 Cancer and Blood Diseases Institute, Cincinnati
Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA. 11 Division of Biostatistics, College of Public Health, The Ohio State
University, Columbus, OH, USA. 12 Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA. 13 Department of
Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK. *email: ramiro.garzon@osumc.edu
NATURE COMMUNICATIONS |         (2019) 10:5351 | https://doi.org/10.1038/s41467-019-13259-2 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Acute myeloid leukemia (AML) is a highly heterogeneousdisease with regard to its underlying genetic abnormalitiesand clinical course1. Recurrent chromosome aberrations
and gene mutations have been implicated in leukemogenesis and
are used in the clinic to risk-stratify treatment of AML patients2.
Mutations in the NPM1 gene are among the most frequent and
clinically relevant genetic alterations in AML, and deﬁne a dis-
tinct subtype of AML in the World Health Organization classi-
ﬁcation of acute leukemias3. NPM1 mutations are detected in
~60% of patients with cytogenetically normal AML (CN-AML)
and associate with a favorable clinical outcome4–6.
The wild-type NPM1 gene encodes an ubiquitously expressed
protein that shows strong nucleolar localization7, shuttles
between the nucleus and cytoplasm8 and regulates important
cellular functions such as transcription9 and maturation10,11 of
ribosomal RNA (rRNA) and nuclear export of ribosomal pro-
teins12. NPM1 mutations in AML result in the introduction of a
nuclear export signal at the C-terminus of the NPM1 protein,
which leads to the aberrant localization of the mutant protein in
the cytoplasm4,13,14. At the molecular level, NPM1-mutated CN-
AML is associated with a distinctive mRNA-expression proﬁle
characterized by HOX gene family overexpression and CD34
negativity6,15. Mechanistically, expression of a humanized mutant
Npm1 allele in a conditional knock-in mouse model causes
HOX gene overexpression and late-onset myeloid leukemia16.
These ﬁndings support the critical role of NPM1 mutations in
leukemogenesis.
Long non-coding RNAs (lncRNAs) constitute a distinct subset
of non-protein-coding RNA molecules that are longer than 200
nucleotides and regulate many key cellular functions17. Deregu-
lated expression of lncRNAs is an important molecular event in
many types of cancer18–23. In AML, prognostic lncRNA tran-
scripts whose expression independently associates with the out-
come of AML patients have recently been identiﬁed24–26. In
addition, recurrent prognostic gene mutations in AML, including
NPM1 mutations, have been reported to associate with distinctive
lncRNA signatures24,25,27. A lncRNA embedded in the HOXB
locus and named HOXB-AS3 was identiﬁed among the most
highly upregulated lncRNAs in CN-AML patients with NPM1
mutations.
HOX genes are important regulators of embryonic and
hematopoietic cell development, which have been implicated in
leukemogenesis28. HOX gene loci also contain lncRNAs that are
involved in cell differentiation and cancer pathogenesis (e.g.,
HOTAIR, HOTTIP, HOTAIRM1), mainly by regulating the
expression levels of protein-coding HOX genes29–31.
Considering the aberrant expression of the HOX genes in AML
with mutated NPM1 (NPM1mut) and the role of lncRNAs in
regulating HOX gene expression, we hypothesized that HOXB-
AS3 overexpression could have biologic signiﬁcance in NPM1mut
AML. Herein, we dissect the functional role of HOXB-AS3 in
NPM1mut AML. We perform assays to identify the protein
interactors of HOXB-AS3 and describe its functional role in
regulating rRNA transcription and ribosomal biogenesis in leu-
kemic blasts. Finally, we demonstrate the potential value of
HOXB-AS3 as a therapeutic target in preclinical AML xenograft
models.
Results
HOXB-AS3 expression in healthy hematopoiesis and AML. We
ﬁrst measured the expression levels of HOXB-AS3 in six AML cell
lines with wild-type NPM1 (NPM1wt) (Kasumi-1, K-562, KG-1a,
MOLM-13, MV-4-11, and THP-1) and in the NPM1mut OCI-
AML3 cell line, which harbors Type A NPM1 mutations, by
custom-designed real-time quantitative PCR (RT-qPCR)
(Supplementary Table 1a). We focused on the HOXB-AS3 tran-
script variant NR_033202.2, which was found to be dominantly
expressed in AML blasts (Supplementary Fig. 1). We found
detectable levels of HOXB-AS3 only in the NPM1mut OCI-AML3
cells (Fig. 1a).
We further analyzed bone marrow (BM) samples from healthy
donors as well as leukapheresis samples from NPM1mut and
NPM1wt AML patients (n= 6 in each group) using RT-qPCR.
Cytogenetic and mutational proﬁles of the AML patients are
provided in Supplementary Table 2. We found that NPM1mut
patients had higher HOXB-AS3 expression than NPM1wt patients
(P= 0.007) or healthy BM cells (P= 0.006; Fig. 1b). There was no
signiﬁcant difference in HOXB-AS3 expression between healthy
BM cells and the NPM1wt AML samples. We further examined
the impact of NPM1mut status on HOXB-AS3 expression in
publicly available data of AML patients previously analyzed with
RNA-seq25. NPM1mut patients (n= 223) had approximately a
three-fold increase in HOXB-AS3 expression compared with
NPM1wt patients (n= 140; Fig. 1c, P < 0.001). HOXB-AS3
upregulation was observed independently of the type of NPM1
mutations (Supplementary Fig 2a, b). Last, we queried datasets of
AML samples and normal hematopoietic cells analyzed with
microarray assays or RNA-seq and deposited in the BloodSpot
portal (www.bloodspot.eu). In keeping with our ﬁndings, HOXB-
AS3 was not expressed in healthy BM cells and was detected in
CN-AML samples and, in particular, in NPM1mut CN-AML
(Supplementary Fig. 3a, c).
HOXB-AS3 does not associate with polysomes in AML cells. To
gain insights into the functional role of HOXB-AS3, we ﬁrst
studied its subcellular localization. We puriﬁed nuclear and
cytoplasmic fractions of OCI-AML3 cells and measured the
abundance of the GAPDHmRNA, ACTBmRNA, and HOXB-AS3
lncRNA in these subcellular compartments. In keeping with their
protein-coding function, the GAPDH and ACTB transcripts were
primarily located in the cytoplasm of OCI-AML3 cells. In con-
trast, HOXB-AS3 was more abundant in the nuclear fraction of
the cells (Fig. 1d). To determine whether HOXB-AS3 has any
protein-coding potential, we used sucrose gradient-based frac-
tionation and performed targeted polysome proﬁling in OCI-
AML3 cells. We measured the abundance of GAPDH mRNA,
ACTB mRNA, HOXB-AS3 lncRNA, and MALAT1 lncRNA,
which is an established non-coding transcript32, on the isolated
fractions. Both GAPDH and ACTB were enriched in the low and
high molecular weight polysomal fractions, whereas HOXB-AS3
and MALAT1, were enriched in the free fractions, indicating that
these transcripts do not interact with the translational machinery
of the blasts (Fig. 1e).
HOXB-AS3 overexpression is driven by NPM1 mutations. To
examine the association between NPM1 mutations and HOXB-
AS3 overexpression, we performed knockdown (KD) experiments
of the NPM1mut allele in OCI-AML3 cells using NPM1mut-
targeting locked nucleic acid (LNA)-modiﬁed gapmer antisense
oligonucleotides (hereafter named gapmers). Electroporation-
mediated delivery of either anti-NPM1mut gapmer (anti-
NPM1mut#1 and anti-NPM1mut#2, Supplementary Table 1b) led
to KD of NPM1mut (Fig. 1f) and a concomitant increase in the
NPM1wt mRNA expression (Fig. 1g). There was no reduction in
the amount of total NPM1 protein (Fig. 1h), while the amount of
mutant NPM1 protein was decreased (Fig. 1i). At 48 h post
electroporation, KD of NPM1mut led to a decrease in HOXB-AS3
RNA abundance (P < 0.001; Fig. 1j).
We also analyzed lineage marker-negative, Kit-positive-
selected murine BM cells, harvested from transgenic mice
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harboring a humanized, mutated Npm1 knock-in allele (Npm1cA/+)
and age-matched wild-type controls (Npm1WT), as previously
described16. Npm1cA/+ mice harbor a four-nucleotide insertion
that corresponds to the Type A NPM1 mutations that are
detected in human AML samples. We measured the expression
levels of a murine lncRNA transcript, which is antisense to
the Hoxb5 and Hoxb6 genes and displays sequence homology
to the human HOXB-AS3, named Hoxb5os. We found Hoxb5os to
be signiﬁcantly upregulated in the Npm1cA/+ mice, compared
with the Npm1WT controls (P < 0.001; Fig. 1k).
HOXB-AS3 expression regulates proliferation of AML cells.
Next, we conducted KD experiments using anti-HOXB-AS3
gapmers. Delivery of a mixture of two gapmers (anti-HOXB-
AS3#1 and anti-HOXB-AS3#2, Supplementary Table 1b) to OCI-
AML3 cells led to a 10-fold decrease of HOXB-AS3 expression
(P= 0.003; Fig. 2a). Cell-cycle analysis based on bromodeox-
yuridine (BrdU) incorporation and 7-actinomycin D (7-AAD)
staining, conducted at 48 h post-delivery of gapmers, showed a
decrease in the fraction of OCI-AML3 cells in S phase upon KD
of HOXB-AS3 (P < 0.001) and an increase in the G2/M phase cells
compared with scramble control (P= 0.006; Fig. 2b, c). Annexin
V/propidium iodide staining analysis showed no difference in
apoptosis between scramble and anti-HOXB-AS3-treated cells
(Supplementary Fig. 4a, b). Colony formation unit (CFU) assays
in methylcellulose-based media showed a decrease in the colony-
forming capacity of OCI-AML3 cells after HOXB-AS3 KD (P=
0.02; Fig. 2d).
In contrast, overexpression of HOXB-AS3 in K-562 cells (P=
0.001; Fig. 2e) led to an increase in the fraction of the proliferating
blasts (P= 0.02; Figs. 2f and g), with a concomitant decrease in
the fraction of cells in the G0/G1 phase (P= 0.008). Taken
together, these data indicate the regulatory effect of HOXB-AS3
expression levels on the proliferative capacity of leukemic blasts.
HOXB-AS3 KD decreases proliferation of AML patient blasts.
We conducted HOXB-AS3 KD experiments in blasts of three
NPM1mut AML patients (pat1, pat2, and pat3). Delivery of anti-
HOXB-AS3 gapmers via electroporation effectively targeted and
downregulated HOXB-AS3 RNA expression in blasts of each
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Fig. 1 HOXB-AS3 lncRNA expression in healthy hematopoietic cells and leukemic blasts. a Relative RNA expression of HOXB-AS3 in seven AML cell lines.
b Relative HOXB-AS3 RNA expression in bone marrow (BM) samples from six healthy donors (hBM), AML blasts from six patients with NPM1mut, and
AML blasts from six patients with NPM1wt, in aggregate. N.S., not signiﬁcant. c HOXB-AS3 RNA expression (depicted as fold change) in younger adult CN-
AML patients with NPM1 wild-type (NPM1wt; n= 140) and in those with mutated NPM1 (NPM1mut; n= 223). d Nuclear versus cytoplasmic localization of
GAPDH, ACTB mRNA, and HOXB-AS3 RNA in OCI-AML3 cells. e Targeted proﬁling of GAPDH, ACTB, HOXB-AS3, and MALAT1 in OCI-AML3 cells in non-
polysome associated (fractions 1–6), 40S, 60S, 80S (fractions 7–11), as well as low (fractions 12–15) and high (fractions 16–20) molecular weight
polysomal fractions, isolated via glucose gradient centrifugation. f–k OCI-AML3 cells treated with scramble versus NPM1mut-targeting gapmers (anti-
NPM1mut#1 and anti-NPM1mut#2). f Relative NPM1mut mRNA, g relative NPM1wt mRNA, h total NPM1 protein, i NPM1mut protein, and j relative HOXB-
AS3 RNA expression in the treated cells. In the presented western blots (h, i), ACTB is also visualized as loading control. k Relative Hoxb5os RNA
expression in BM samples from three Npm1WT and two Npm1cA/+ mice. Unless otherwise stated all samples were analyzed in technical triplicates. P values
were calculated using paired two-sided t-tests. In the ﬁgures, heights of boxplots indicate mean values with standard deviation. Error bars indicate highest
and lowest values in each population. Source data are provided as a Source Data ﬁle.
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patient (Fig. 3a). HOXB-AS3 KD led to a signiﬁcant decrease in
the number of formed colonies in CFU assays, compared with
scramble control (Fig. 3b). In contrast, transfection with anti-
HOXB-AS3 gapmers had no effect in the proliferation of leukemic
blasts of NPM1wt patients or the growth and differentiation of
healthy hematopoietic progenitor cells (CD34+ selected umbili-
cal cord blood cells, Supplementary Fig. 5a–e).
HOXB-AS3 KD prolongs survival of xeno-transplanted mice.
To evaluate the effect of HOXB-AS3 KD in AML blasts in vivo, we
conducted experiments in patient-derived xenograft (PDX)
mouse models. We used published protocols33 to transplant
busulfan-pre-treated NOD-scid IL2Rgammanull (NSG) mice with
leukemic blasts of a NPM1mut AML patient in two independent
experiments. Nine mice engrafted with patient AML blasts were
treated with either anti-HOXB-AS3 gapmers (n= 5) or scramble
control (n= 4) for 2 weeks for evaluation of the in vivo HOXB-
AS3 KD efﬁcacy. Treatment with lipid nanoparticle (LNP)-for-
mulated anti-HOXB-AS3 gapmers led to downregulation of
HOXB-AS3 expression in human CD45-selected AML blasts
isolated from the BM of the treated mice (P < 0.001; Fig. 3c).
Larger cohorts of mice were then engrafted with blasts. Ten days
after transplantation, mice were divided into anti-HOXB-AS3
(n= 11) or scramble treatment arms (n= 11) and were mon-
itored for survival. An overview of the experimental design is
provided in Fig. 3d. In vivo HOXB-AS3 KD led to signiﬁcant
prolongation of survival of the treated mice compared with the
scramble control. The median survival of the scramble treated
mice was 63 days, whereas it was not reached after 100 days of
treatment for the HOXB-AS3 KD group (P < 0.001; Fig. 3e).
Hoxb5os KD decreases proliferation of murine AML blasts. To
further validate our observations of the HOXB-AS3 functional
signiﬁcance, we employed CRISPR-Cas9 disruption of the
-murine synonymous- Hoxb5os transcript, in two recently
developed mouse models of Npm1cA/+-driven AML34. Speciﬁ-
cally, we transduced the Rosa26Cas9/+; Npm1cA/+; Flt3ITD/+ and
the Rosa26Cas9/+; Npm1cA/+; NrasG12D/+ cell lines with four
combinations of dual guide RNAs (gRNA1-gRNA4, Supple-
mentary Table 1c), which targeted the Hob5os region and co-
expressed blue ﬂuorescent protein (BFP). Similar BFP-expressing
empty vectors were used as negative controls, whereas Aurkb
targeting gRNAs were used as pan-essential positive controls34.
Transduced cells were then grown in competitive co-culture
conditions with non-transduced cells. Disruption of Hoxb5os led
to a gradual reduction in the BFP-expressing cells after 15 days of
culture in both Npm1cA/+-harboring cell lines, while cells trans-
duced with control vectors remained unaffected (Figs. 3f and g).
HOXB-AS3 does not affect HOX gene expression. Several HOX
loci-embedded lncRNAs are important molecular players in
cancer by regulating in cis or in trans expression levels of HOX
genes29–31. To examine whether HOXB-AS3 regulates HOX gene
expression we performed RNA-seq analyses in scramble versus
anti-HOXB-AS3-treated OCI-AML3 cells (12, 24, and 48 h) and
in blasts of four NPM1mut AML patients (24 h post transfection).
HOXB-AS3 KD had no effect on the expression levels of the HOX
genes that are detectably expressed in NPM1mut AML patient
blasts (Supplementary Fig. 6a, b) or the OCI-AML3 cells (Sup-
plementary Fig. 6c–g). We validated these ﬁndings for a sub-
set of HOX transcripts in OCI-AML3 cells by RT-qPCR
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(Supplementary Fig. 6h–k). As HOXA9 overexpression has leu-
kemogenic potential35, we further assessed HOXA9 protein levels
by western blotting (WB). No difference in HOXA9 levels was
detected between OCI-AML3 cells treated with scramble or anti-
HOXB-AS3 gapmers (Supplementary Fig. 6l).
The ErbB3-binding protein 1 (EBP1) interacts with HOXB-
AS3. Many lncRNAs regulate key cellular processes by interacting
with speciﬁc proteins29,36. Thus, to further study the function of
HOXB-AS3, we interrogated its interactions with the proteome of
OCI-AML3 cells by performing RNA pull-down experiments and
characterization of ribonucleoprotein complexes. To this end, we
applied a modiﬁed version of the RNA-antisense puriﬁcation
technique36. In brief, we used biotinylated probes to capture
either the HOXB-AS3 lncRNA or the U1 transcripts (Supple-
mentary Table 1e) (Fig. 4a–c). Tandem mass spectrometry and
comparative proteomic analyses of the HOXB-AS3 and U1 eluates
were conducted and the putative HOXB-AS3 and U1 interactors
are listed in Supplementary Table 3. Five proteins, reported to
form the U1-complex (SNRNP70, SNRPE, SNRPD2, SNRPD3,
and SNRPA)37–39 were identiﬁed as U1-interactors.
We also identiﬁed 22 putative HOXB-AS3 interactors. Valida-
tion experiments by RNA immunoprecipitations (RIP) were
conducted for nine of these 22 proteins and signiﬁcant HOXB-
AS3 enrichment was found in seven of them (Fig. 4d). Of
the tested candidates, EBP1 was the strongest interactor of
HOXB-AS3, as it bound to approximately 80% of the measured
HOXB-AS3 in the input sample. We tested the speciﬁcity of the
EBP1-HOXB-AS3 interaction by proﬁling the RNA eluates that
were isolated after EBP1 immunoprecipitations for other protein-
coding and non-coding RNAs. In contrast to HOXB-AS3, none of
the tested transcripts showed signiﬁcant enrichment compared
with controls, indicating that the interaction of EBP1 with
HOXB-AS3 is speciﬁc (Supplementary Fig. 7).
HOXB-AS3 regulates the interaction of EBP1 with NPM1.
EBP1 is an RNA-binding protein ﬁrst identiﬁed as an interactor
of the ErbB3 receptor in human breast cancer cells. Two distinct
EBP1 isoforms (p42 and p48) that differentially regulate
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proliferation and viability of cells40 have previously been identi-
ﬁed. To elucidate if an EBP1 isoform preferentially interacts with
HOXB-AS3, we cloned, labeled with a FLAG tag and over-
expressed p42 and p48 in K-562 cells, which were co-transfected
with HOXB-AS3-overexpressing vectors. RIP experiments showed
that HOXB-AS3 interaction with p48 was signiﬁcantly stronger
compared with the HOXB-AS3-EBP1p42 interaction (Supple-
mentary Fig. 8).
Furthermore, the EBP1 protein has been reported to interact
with NPM1 in the nucleolus and to regulate rRNA maturation41.
EBP1 has also been shown to regulate transcription of rRNA
species in AML cells42. Given this background, we examined the
interaction of EBP1 and NPM1 proteins in the context of
heterozygous NPM1 mutations. We validated the EBP1-NPM1
interaction in nuclear lysates of OCI-AML3 cells by reciprocal co-
immunoprecipitations (Figs. 4e and f). Similar experiments with a
mutant NPM1-speciﬁc antibody showed that it is the wild-type
NPM1 protein that primarily interacts with EBP1 (Supplemen-
tary Fig. 9). We next investigated how the HOXB-AS3 levels affect
the formation of the EBP1-NPM1 complex. HOXB-AS3 KD in
OCI-AML3 cells led to a decrease in the interacting amounts of
EBP1 and NPM1 (Figs. 4g–j). HOXB-AS3 KD had no effect in
EBP1 mRNA or protein abundance in the transfected cells
(Supplementary Fig. 10).
The HOXB-AS3-EBP1-NPM1 complex regulates rRNA tran-
scription. EBP1 has been shown to interact with NPM1 in the
nucleus and independently regulate rRNA transcription in AML
cells41,42. We therefore examined whether HOXB-AS3 modulates
the transcriptional activity at the ribosomal DNA (rDNA) locus
in NPM1mut AML cells. We measured rRNA abundance as
previously described42 and found that HOXB-AS3 KD led to a
decrease in the transcribed rRNA in OCI-AML3 cells (P < 0.001;
Fig. 5a). In addition, HOXB-AS3 KD led to a reduction in the
occupancy of the rDNA-promoter by RNA Polymerase I
(POLR1A) in chromatin-immunoprecipitation (ChIP) experi-
ments (P < 0.001; Fig. 5b). Polysomal proﬁling revealed an overall
reduction of the 40S and 60S ribosomal subunits as well as a
reduction in the formed monosomes (80S) and polysomes upon
HOXB-AS3 KD (Fig. 5c). Consequently, in vitro labeling of the de
novo synthesized polypeptides by O-proargyl-puromycin (OPP)
indicated that HOXB-AS3 KD led to a reduction in protein
synthesis of OCI-AML3 cells, compared with scramble control
(P= 0.003; Figs. 5d and e). Finally, short-term in vivo treatment
of human AML blasts in murine xenografts revealed that HOXB-
AS3 KD led to a decrease in the amount of the transcribed rRNA
species (P < 0.001; Fig. 5f) and a decrease in the de novo protein
synthesis in these cells (P= 0.01; Figs. 5g and h).
Inversely, overexpression of HOXB-AS3 in K-562 cells led to an
increase in the abundance of the transcribed rRNA compared
with the empty vector control (P < 0.001; Fig. 5i). Overexpression
of HOXB-AS3 in K-562 cells also led to increased occupancy of
the rDNA promoter by POLR1A (P= 0.002; Fig. 5j). Further, we
conducted experiments with a luciferase-reporter system of
POLR1A activity described previously43, which consists of an
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empty control (pIRES-Luc) and the rDNA promoter-containing
(pHrD-IRES-Luc) reporter vectors. K-562 cells transfected with
the pHrD-IRES-Luc showed an approximately 10-fold increase
in the relative reporter activity, compared with cells transfected
with the pIRES-Luc. This increase was signiﬁcantly higher when
K-562 cells were concomitantly transfected with a HOXB-AS3-
overexpressing vector versus an empty pcDNA3 vector control
(P= 0.002; Fig. 5k). Finally, HOXB-AS3 overexpression led to an
increase in the de novo protein synthesis of the transfected K-562
cells (P= 0.001; Fig. 5l).
HOXB-AS3 guides EBP1 to the rDNA locus. We found that
HOXB-AS3 expression levels impacted on the interaction of EBP1
with NPM1 and affected the EBP1-NPM1 complex formation. As
EBP1 was shown to directly bind to HOXB-AS3, while NPM1 was
not (either in the RAP screening or in subsequent RIP experi-
ments), we hypothesized that HOXB-AS3 could have a guide-
RNA function that regulates the localization of EBP1 to the
rDNA locus.
To test this hypothesis, we studied the interaction of EBP1 with
the rDNA promoter in the presence or absence of HOXB-AS3.
HOXB-AS3 KD reduced the amount of EBP1 that was bound to
the rDNA promoter, as measured by ChIP assays (P= 0.02;
Fig. 5m). This effect was rDNA speciﬁc and binding of EBP1 on
the E2F1 gene promoter, which has previously identiﬁed as an
EBP1 target44 was not affected by HOXB-AS3 KD (Supplemen-
tary Fig. 11). We also evaluated the occupancy of the rDNA
promoter by the NPM1 protein and found that HOXB-AS3 KD
led to reduction in the amount of NPM1 that interacted with the
rDNA chromatin (Supplementary Fig. 12). In addition, RAP-
DNA experiments showed a signiﬁcant enrichment of the rDNA
promoter region in the HOXB-AS3-bound DNA compared with
control samples (P= 0.02; Fig. 5n), while no difference in
enrichment of the ACTB promoter (which served as a negative
control) was noted.
Characterization of the HOXB-AS3-EBP1 interaction. To
identify speciﬁc regions of HOXB-AS3 that mediate the HOXB-
AS3-EBP1 interaction, we generated ﬁve truncated variants, each
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of which sequentially lacked ~100 nucleotides (i.e., regions 1–5),
compared with the wild-type HOXB-AS3 sequence (HOXB-
AS3wt; Fig. 6a). We overexpressed the HOXB-AS3wt and the
HOXB-AS3 truncated variants in K-562 cells and then conducted
RIP experiments for the EBP1 protein. All truncated variants
were expressed at similar levels (Supplementary Fig. 13). In these
experiments variant 2, which lacks region 2 (nucleotides 95–195
of HOXB-AS3wt), showed decreased capacity to interact with
EBP1 (Fig. 6b). The function of the region 2 as a protein binding
site was speciﬁc for EBP1; other HOXB-AS3 binding proteins that
were tested (NONO, PHB1) showed different patterns of inter-
action with the HOXB-AS3 truncated variants (Supplementary
Fig. 14).
Moreover, we used the T7 RNA polymerase to generate
biotinylated transcripts of the HOXB-AS3wt or the HOXB-AS3
truncated variants. After incubating biotinylated transcripts with
nuclear lysates of K-562 cells, we examined their association with the
EBP1 protein. In agreement with the RIP assays, the variant 2 bound
to a lesser amount of the EBP1 protein, compared with the HOXB-
AS3wt and the other HOXB-AS3 truncated variants (Fig. 6c).
Overexpression experiments of the HOXB-AS3wt and trun-
cated variants in K-562 cells showed that only the full HOXB-AS3
sequence and variant 1 increased the abundance of rRNA and
generated a proliferative phenotype (Figs. 6d and e).
To further study the mechanistic basis of the interaction
HOXB-AS3 with the rDNA promoter we performed RAP-DNA
experiments in K-562 cells that were transfected with either the
HOXB-AS3wt or each of the truncated HOXB-AS3 variants. We
captured the HOXB-AS3 transcripts and interrogated the HOXB-
AS3-interacting chromatin for enrichment of the rDNA promo-
ter. Deletion of region 5 of HOXB-AS3 abrogated the enrichment
of the rDNA promoter sequence that was observed with HOXB-
AS3wt and the other truncated variants, indicating that region 5 is
necessary for the interaction between HOXB-AS3 and the rDNA
promoter (Fig. 6f). Furthermore, we used an in silico approach
[i.e., the European Bioinformatics Institute Sequence Aligner Tool
(SAT)] to analyze the interaction between the nucleotide
sequences of the different HOXB-AS3 regions and the rDNA
promoter. While all tested regions showed some level of
complementarity and interaction, region 5 was predicted to
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interact most avidly with the rDNA promoter, as indicated by the
highest SAT score (Fig. 6g).
Discussion
Deregulation of lncRNA expression is gaining recognition for its
important role in cancer pathogenesis. NPM1mut-associated
lncRNA signatures in younger and older adults with CN-AML
have previously been identiﬁed24,25, but the functional sig-
niﬁcance of the identiﬁed lncRNA transcripts was unknown.
HOXB-AS3, a lncRNA embedded in the HOXB locus, was among
the most highly upregulated lncRNAs in NPM1mut AML
patients. Here, we provide evidence that the upregulation of
HOXB-AS3 is driven by the presence of NPM1 mutations and
that depletion of HOXB-AS3 has an anti-leukemic effect.
Knockdown experiments of HOXB-AS3 in vitro, resulted in a
consistent decrease in the proliferating capacity of the leukemic
blasts. In contrast, overexpression of HOXB-AS3 led to an
increase in the proliferative fraction of leukemic cells. Knock-
down of HOXB-AS3 in a murine PDX model showed an anti-
leukemic effect and led to prolongation of survival of the treated
mice. It is noteworthy that the effect of the in vitro KD of HOXB-
AS3 was less pronounced than the potent anti-leukemic effect of
in vivo HOXB-AS3 targeting. Among possible reasons that could
account for this difference is the fact that the in vitro experiments
evaluated a transient KD of the HOXB-AS3 transcript, whereas
during the in vivo experiments treatment with anti-HOXB-AS3
gapmers was continuous. Moreover, the interaction with the bone
marrow microenvironment, which is present in the in vivo stu-
dies but cannot be fully recreated in vitro, could also potentially
impact on the effects of HOXB-AS3 depletion. Nevertheless, the
phenotypic effects and the molecular pathways that were affected
by the downregulation of HOXB-AS3 were concordant in both
experimental settings.
To identify the mechanism by which HOXB-AS3 expression
affects cell proliferation, we ﬁrst evaluated the effect of HOXB-
AS3 KD on the expression levels of other HOX genes. Surpris-
ingly, HOXB-AS3 KD did not signiﬁcantly affect the mRNA levels
of any of the HOX genes tested or the level of HOXA9 protein.
This distinguishes HOXB-AS3 from the majority of the other
HOX loci-embedded lncRNAs, which have been shown to act as
regulators of HOX gene expression. We then focused on the
interactions of HOXB-AS3 with the proteome of OCI-AML3 cells.
We performed RNA pull-down experiments followed by tandem
mass spectrometry analyses and identiﬁed the EBP1 protein as an
avid binder of HOXB-AS3. EBP1 is an RNA-binding protein,
which has been previously shown to regulate the proliferative
capacity of cancer cells40. EBP1 has also been implicated in rRNA
transcription and ribosome biogenesis both independently42 and
via its interaction with NPM141.
In health and disease, rRNA transcription is a highly dynamic
process that is tightly regulated; the multiple copies of the rDNA
across the genome allow the cells to ﬁne-tune and adjust the
output of rRNA according to external stimuli and the availability
of nutrients45. Importantly, deregulation of rRNA transcription is
a molecular pathway, which is implicated in cell proliferation46
and is relevant for leukemogenesis47. Transcriptional activity of
the rDNA locus and ribosome biogenesis are processes dependent
on functional NPM1 alleles. The C-terminus-mutated NPM1
protein, which is the result of the AML-related mutations in the
NPM1 gene, does not associate with the rDNA chromatin48 and
is translocated (together with a fraction of bound wild-type
NPM1 protein) to the cytoplasm49. The reduced amount of
residual NPM1 in the nucleolus is thought to affect nucleolar
integrity and pose a molecular vulnerability in the NPM1mut
AML cells49. We therefore hypothesized that in the presence of
heterozygous NPM1 mutations, a potential regulatory role of the
HOXB-AS3-EBP1 complex in rRNA transcription could have
important functional signiﬁcance.
Indeed, we could show that in NPM1mut AML blasts, HOXB-
AS3 affects the interaction of EBP1 with NPM1 in the nucleus.
Upon depletion of HOXB-AS3 in OCI-AML3 cells, a lesser
amount of NPM1 was found to interact with EBP1. In addition,
we found that HOXB-AS3 KD impacts on the rRNA transcription
and, subsequently, the process of protein synthesis in AML blasts.
In this sense, the functional role of HOXB-AS3, in the context of
heterozygous NPM1 mutations, could be regarded as a compen-
satory mechanism; in parallel to translocating NPM1 to the
cytoplasm, the presence of NPM1 mutations causes the aberrant
overexpression of the HOXB-AS3 lncRNA. HOXB-AS3 interacts
with and guides EBP1 to the rDNA locus and augments the
interaction of EBP1 with the residual NPM1 in the nucleolus. In
this manner, HOXB-AS3 helps maintain adequate amounts of
rRNA and maximize the efﬁciency of the protein translating
machinery in the metabolically demanding state of constant
proliferation (Fig. 7a–d).
Huang et al.50 have recently published an elegant study on the
functional signiﬁcance of HOXB-AS3 expression in colorectal
cancer cells. They identiﬁed a small peptide encoded by the
NR_033201.2 variant of HOXB-AS3, which has a tumor sup-
pressive role. While recent studies highlight the dual nature of
RNA transcripts that deploy both production of peptides and
non-protein-coding mechanisms to exert their effects on cells51,
our data do not support that this is the case for HOXB-AS3 in
AML. We found the HOXB-AS3 lncRNA to be upregulated in
NPM1mut leukemic blasts and to be absent in healthy BM cells,
whereas, in colorectal cancer, it was the downregulation of
HOXB-AS3 that associated with aggressive malignant phenotype.
Moreover, we show that the HOXB-AS3 lncRNA is primarily
located in the nucleus of AML blasts and found no evidence that
it associates with polysomal fractions. Our RAP experiments also
showed no enrichment of ribosomal proteins in the HOXB-AS3-
eluates compared with the U1-pull-downs. In addition, it is worth
pointing out that the HOXB-AS3 transcript variant that we found
to be functionally relevant in AML shows limited overlap with the
HOXB-AS3 variant that was characterized in colorectal cancer
(Supplementary Fig. 1). Collectively, these data suggest that in
NPM1mut AML blasts HOXB-AS3 acts as a genuinely non-
protein-coding RNA and displays a different mechanism of
function from the one that has been described in colorectal
cancer.
The in vivo HOXB-AS3 KD experiments that we conducted to
evaluate the functional relevance of HOXB-AS3 in NPM1mut
AML also underscore the potential therapeutic value of HOXB-
AS3 depletion. The absence of HOXB-AS3 expression in healthy
hematopoietic BM cells makes it an attractive therapeutic target.
We optimized a LNP-based method for packaging and delivering
anti-HOXB-AS3 gapmers in vivo with no signiﬁcant toxicities.
Depletion of HOXB-AS3 led to signiﬁcant prolongation of the
overall survival of mice transplanted with AML patient blasts. To
our knowledge, this is one of the few preclinical models, in which
in vivo targeting of a lncRNA transcript as single-agent therapy
yielded therapeutic results52. Despite the preliminary nature of
this data and the additional experiments that are warranted (to
deﬁne optimal dosing, treatment schedule, delivery method etc.),
we believe that the in vivo anti-leukemic effect of HOXB-AS3
depletion is promising and supports the feasibility of lncRNA
targeting in the treatment of AML.
Methods
Acute myeloid leukemia patients and healthy BM donors. For association
analyses of HOXB-AS3 expression by NPM1 mutational status, publicly available
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data of CN-AML patients were further analyzed. For in vitro and in vivo functional
experiments, leukapheresis samples of AML patients were used. The cytogenetic
and gene mutational proﬁles of all patients, whose samples were used in functional
experiments, are provided in Supplementary Table 2. BM-isolated mononuclear
cells from six healthy donors were purchased from an institutional Biobank Core
Facility. For in vitro and in vivo functional experiments, leukapheresis samples of
AML patients deposited in the Leukemia Tissue Bank of The Ohio State University
were used. All patients and healthy donors were de-identiﬁed and had provided
written informed consent for the use of their biologic specimens for research
purposes according to the Declaration of Helsinki. All relevant ethical regulations
for work with human participants were in accordance with the Institutional Review
Board (IRB), protocol number 1997C0194 of The Ohio State University.
Acute myeloid leukemia cell lines. Kasumi-1, KG-1a, K-562, MV-4-11, and
THP-1 cells were purchased from the American Type Culture Collection (ATCC)
cell repository. MOLM-13 and OCI-AML3 cells were purchased from the Leibniz
Institute DSMZ-German Collection of Microorganisms and Cell Cultures. The
HEK 293T/17 cells were purchased for the ATCC cell repository. Presence of a type
A NPM1 mutations in OCI-AML3 cells was conﬁrmed by PCR ampliﬁcation and
Sanger sequencing. All other cell lines were recently obtained from the respective
cell repositories and were not further characterized.
Culture conditions of acute myeloid leukemia patient blasts and cell lines. For
in vitro experiments AML patient blasts were cultured in StemSpan SFEM med-
ium, supplemented with 10% BIT serum substitute (STEMCELL Technologies
Inc.), 1% antibiotic-antimycotic solution (Anti-anti, Gibco), 1% L-Glutamine
(Gibco) and cytokines [rmScf (100 ng/ml), rhTPO (50 ng/ml), rhFLT3-ligand
(40 ng/ml), rhIL-3 (10 ng/ml), and rhIL-6 (10 ng/ml)]. All cytokines were pur-
chased from PeproTech. All cultures were performed in 37 °C/5% CO2.
KG-1a, K-562, MV-4-11, MOLM-13, OCI-AML3, and THP-1 cells were
cultured in Roswell Park Memorial Institute (RPMI-1640) medium (Sigma),
supplemented with 10% fetal bovine serum (FBS, Sigma), 1% antibiotic-
antimycotic, and 1% L-glutamine. Kasumi-1 cells were cultured in similar medium
substituted with 20% FBS. HEK 293T/17 cells were grown in Dulbecco’s modiﬁed
Eagle medium (DMEM) medium (Sigma), supplemented with 10% FBS and 1%
antibiotic-antimycotic. All cell line cultures were performed in 37 °C/5% CO2.
Human AML patient-derived xenografts. For in vivo studies, NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice were used as recipients of NPM1mut AML patient
blasts. Mice were pretreated with busulfan [20 mg/kg weight with intraperitoneal (i.
p.) injections] and blasts of each patient were injected via tail vein 1-day post
treatment. Female mice of 6–8 weeks of age were used for experiments. All animal
studies were conducted according to protocols approved by the Institutional
Animal Care and Use Committees of The Ohio State University (IRB protocol
#2018C0072).
On day 10 post transplantation, NSG mice were assigned to groups to receive
anti-HOXB-AS3 or non-targeting-control treatment. Assignment to two groups
was made based on the weight of each mouse prior to gapmer treatment and
caution was taken so that weight distributions were similar between the groups.
Blood samples were periodically acquired and analyzed by ﬂow cytometry
[stained with antibodies against human CD45 and mouse 45.1 (BD Biosciences), at
1:1000 dilution]. Only mice that showed ≥5% of human leukemic blasts were
included in the study.
RNA isolation and real-time quantitative PCR. RNA isolation was performed
with the Trizol reagent according to the instructions of the manufacturer (Invi-
trogen). Reverse transcription was performed with the Superscript III single strand
RT kit, according to the instructions of the manufacturer (Invitrogen). All custom-
designed real-time qPCR (RT-qPCR) primers were synthesized by IDT Inc. as a
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Fig. 7 Schematic depiction of the proposed functional role of HOXB-AS3 in NPM1mut AML. a Healthy state. NPM1 protein is in its wild-type conﬁguration,
resides in the nucleolus and regulates ribosome biogenesis. b NPM1 mutations lead to a reduction of the amount of NPM1 protein in the nucleolus and a
reduction in the total amount of the transcribed rRNA. c NPM1 mutations also lead to aberrant upregulation of the HOXB-AS3 lncRNA. d HOXB-AS3
interacts with and guides EBP1 to the nucleolus. The increased amount of EBP1 interacts with the residual NPM1 and increases the output of
transcribed rRNA.
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for-fee service. RT-qPCR experiments were conducted in a RT-qPCR machine
(Applied Biosystems, 7500 Real Time PCR System) in the conditions speciﬁed by
the manufacturer.
Flow cytometry analyses. Cell-cycle and apoptosis analyses were performed with
the BrdU and the Annexin/PI staining kits of BD Pharmingen. Experiments were
analyzed with ﬂow cytometry on an LSRII instrument, according to the instruc-
tions of the manufacturer. Gating strategies are exempliﬁed in Supplementary
Fig. 15.
Cell fractionation, polysome proﬁling, and isolation. For the separation of OCI-
AML3 cells in nuclear and cytoplasmic fractions 3 × 106 cells were harvested and
lysed by use of the NePER cell fractionation kit (Thermo Scientiﬁc) according to
the instructions of the manufacturer.
For the isolation of polysome fractions and polysome proﬁling, 10 × 106 OCI-
AML3 cells were grown at a concentration of 5 × 105 cells/ml. Prior to lysis, a
freshly prepared DMSO-solution of cycloheximide was added to the medium to a
ﬁnal concentration of 100 µg/ml. Cells were incubated for 10 min at 37 °C/5% CO2,
washed in cycloheximide-containing PBS (100 µg/ml) and lysed in lysis buffer [(50
mM Tris-HCl pH 7.5, 10 mM KCl; 10 mM MgCl2, 150 mM NaCl, 2 mM DTT, 0.5
mM PMSF, 200 μg/l cycloheximide, 0.2% IGEPAL, and protease inhibitors:
leupeptin (Sigma-Aldrich), pepstatin A (Sigma-Aldrich), and aprotinin (Sigma-
Aldrich)]. Lysates were incubated on ice for 10 min and cleared by centrifugation in
a tabletop microcentrifuge (16,000 × g, 10 min, 4 °C). The supernatants were
collected into fresh tubes and ﬂash frozen until polysome isolation or proﬁling was
conducted.
Cytoplasmic extracts were thawed on ice. The equivalent of 4.5 million OCI-
AML33 cell lysates was layered onto each 11 ml of 10–50% linear sucrose gradient.
Gradients were then centrifuged (35,000 rpm, 3 h, 4 °C) in a Sorvall-TH641 rotor at
4 °C. Gradient fractions were collected at 500 µl intervals with continuous
measurement of UV absorbance at 254 nm.
For measurements of RNA transcripts, each isolated polysomal fraction was
mixed with 1 ml of Trizol reagent and standard RNA extractions were performed.
RNA samples were pooled together prior to reverse transcription and RT-qPCR.
Cell pellets of 0.45 million cells were lysed with Trizol reagent and standard RNA.
The unfractionated cells were used as input material, to determine the relative
abundance of the transcripts on each isolated fraction of the sucrose gradient.
Gene knockdowns and overexpression. For the knockdown (KD) of genes in
OCI-AML3 cells and samples from NPM1mut AML patients we used custom-
designed locked nuclei acid-modiﬁed RNaseH recruiting oligonucleotides (gap-
mers, Exicon A/S). The sequences of the gapmers are provided in Supplementary
Table 1. For the in vitro delivery of the gapmers, the Nucleofector device (Lonza)
and the corresponding reagents (Solution T for OCI-AML3 cells and human
Monocyte Solution for AML blasts, Lonza) were used according to the instructions
of the manufacturer (program X-001 for OCI-AML3 cells and program Y-001 for
patient blasts). Anti-HOXB-AS3, anti-NPM1mut or non-targeting control gapmers
were delivered at a ﬁnal concentration of 500 nM.
For the in vivo KD of the HOXB-AS3 lncRNA, HOXB-AS3-targeting gapmers
or non-targeting controls were packaged into cationic lipid nanoparticles (LNPs)
conjugated with human transferrin. In brief, the LNPs consisted of 1, 2-dioleoyl-3-
trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) at a molar ratio of 1-to-1. DOTAP (18.8 mg) and DOPC
(21.2 mg) were dissolved in 1 ml of ethanol and were then injected into 9 ml of
HEPES buffer (20 mM, pH 7.4). After 5 min of incubation in a water bath
sonicator, the nanoparticles were passed through a 0.22 µm sterile ﬁlter. Solutions
of gapmers were mixed with lipids at a 1-to-10 weight ratio, vortexed and
incubated at room temperature for 10 min. The lipid-oligo formulation was then
mixed with a human transferrin solution. The mixtures were vortexed and
sonicated in a water bath sonicator for 10 min and incubated for an hour at 37 °C.
For the ﬁrst week of treatment mice were treated with i.v. injections on days 1, 3,
and 5 (of 5 mg of gapmers/kg weight) and i.p. injections on days 2 and 4 (of 10 mg
of gapmers/kg weight). The mice received only i.p. injections (5/week) for the
remainder of the treatment course.
Delivery of the control or HOXB-AS3-overexpressing pcDNA3 vectors to K-562
cells was performed with electroporation with the Nucleofector device according to
the instructions of the manufacturer (Solution V, program T-016). Two
micrograms of vector were used per reaction.
In vitro colony-forming assays. For colony formation unit assays with AML cell
lines, the cells were electroporated, cultured for 24 h and then mixed with basic
pre-warmed methylcellulose-based medium without cytokines (MethoCult H4100,
STEMCELL Technologies Inc), supplemented with 10% FBS. AML cells were
seeded at a concentration of 1000 cells/ml, and colonies were counted on day 14.
For CFU assays with human AML patient blasts, the cells were electroporated,
cultured for 24 h (as described in the section detailing culture conditions) and then
mixed with pre-warmed methylcellulose-based medium (Methocult H4034
Optimum, STEMCELL Technologies Inc.) according to the instructions of the
manufacturer. Leukemic blasts were seeded at a concentration of 50,000 blasts/ml
of medium and colonies were counted on day 14.
CRISPR/Cas9 silencing of Hoxb5os in Npm1cA/+ cell lines. For disruption of the
Hoxb5os transcript with the CRISPR/CAs9 technique, guide RNAs targeting two
separate regions of the transcript were cloned into the dual guide expressing
pKLV2-.2-h7SHgRNA5(SapI)-U6gRNA5(BbsI)-PGKpuroBFP-W lentiviral vectors
as previously described33. BM-derived AML cells from Rosa26-EF1-Cas9 mice
were cultured in vitro in the presence of cytokines. Disruption of individual can-
didate genes was performed by transduction with lentivirus expressing gene-
speciﬁc guide RNAs (gRNA) and blue ﬂuorescent protein (BFP). The impact of
gene disruption on AML cell growth was determined using competitive co-culture
of transduced (BFP+) versus non-transduced (BFP−) cells. In brief, transduced
cells were allowed to grow in the presence of non-transduced cells while the per-
centage of BFP+ cells was measured by ﬂow cytometry on days 4, 8, 11, and 15. For
the depiction of the results, the percentage of BFP+ cells on day 4 was used as
reference. Based on previously published results34, gRNAs targeting the Aurkb gene
were used as a pan-essential positive control. Sequences of the gRNAs used are
provided in Supplementary Table 1d.
Transcriptome analyses. Libraries for RNA-seq experiments were generated as
follows: after Trizol-based RNA extraction, total RNA extracted from blasts of four
different NPM1mut AML patients and OCI-AML3 cells was used for library
generation. Patient AML blasts were treated with anti-HOXB-AS3 or non-targeting
scramble control gapmers and harvested at 24 h post electroporation. OCI-AML3
cells were treated similarly and harvested at 12, 24, and 48 h post electroporation.
Samples were assessed for quality on an Agilent 2100 Bioanalyzer (BioA) using the
RNA 6000 Nanochip and for quantity on a Qubit 2.0 Fluorometer (Agilent
Technologies) using the RNA HS Assay Kit. Samples with an RNA integrity
number (RIN) >7, with no visible sign of genomic DNA (gDNA) contamination
and a concentration of >40 ng/μl were used for mRNA library generation. RNA-seq
libraries were prepared using the Illumina TruSeq Stranded mRNA Sample Prep
Kit with poly-A-tail selection of the RNA transcripts (#RS1222201) according to
the instructions of the manufacturer. Sequencing was performed with the Illumina
HiSeq 2500 system using the HiSeq version 3 sequencing reagents to an approx-
imate cluster density of 800,000/mm2. Image analysis, base calling, error estima-
tion, and quality thresholds were performed using the HiSeq Controller Software
(version 2.2.38) and the Real Time Analyzer (RTA) software (version 1.18.64).
Analysis of RNA sequencing data were performed as follows: transcript
abundance was quantiﬁed from the RNA-seq data using Kallisto53, with a reference
transcriptome consisting of Homo sapiens GRCh38 protein-encoding and non-
coding transcripts except rRNAs; the strand-speciﬁc option of “ﬁrst read reverse”
was chosen; 100 bootstrap subsamples were generated for each RNA-Seq sample to
estimate inferential variance. Gene-level differential expression analysis was
performed on the kallisto output using linear models via Sleuth54 (https://doi.org/
10.1038/nmeth.4324). For patient data, patient identiﬁer was included as a ﬁxed
effect to conduct a paired analysis; for cell line data, repeated measures ANOVA
was used to test for differences between scramble and HOXB-AS3 KD. Likelihood
ratio tests were performed to determine whether each gene showed signiﬁcant
differential expression between control (scramble) and HOXB-AS3 KD treatments.
A false discovery rate threshold FDR < 0.0555 was used to detect signiﬁcance in
differential expression between scramble and HOXB-AS3 KD samples.
RNA-antisense puriﬁcation experiments. RNA-protein complex pull-down
experiments were conducted according to a modiﬁed version of the RAP-MS
protocol published by McHugh et al.36. In brief, AML blasts were cross-linked in
batches of 20 × 106 cells via exposure to 8000 J/m2 of ultraviolet (UV) irradiation.
Cells were lysed in lysis buffer (10 mM Tris-HCl, 500 mM LiCl, 0.5% dodecyl
maltoside (DDM), 0.2% sodium dodecyl sulfate (SDS), 0.1% sodium deoxycholate),
sonicated and treated with DNAse I (Norgen Biotek). Lysates were mixed with
hybridization buffer (10 mM Tris-HCl, 5 mM EDTA, 500 mM LiCl, 0.5% DDM,
0.2% SDS, 0.1% sodium deoxycholate, 4 M urea, 2.5 mM TCEP) and spun down in
a tabletop centrifuge (16,000 × g, 10 min, 4 °C). The supernatants were pre-cleaned
by incubation (intermittent shaking at 1100 rpm, 30 min, 37 °C) with streptavidin-
coated magnetic beads (Dynabeads MyOne, Streptavidin C1, Life Technologies).
After removal of beads, the lysates were incubated with biotinylated probes (2 μg of
probes per 20 × 106 cells) that were complementary to either the HOXB-AS3 or the
U1 transcripts. The sequences of the biotinylated probes are provided in Table 1.
Probes and lysates were allowed to hybridize by incubation for 2 h at 67 °C with
intermittent shaking at 1100 rpm. Streptavidin-coated magnetic beads were used
for the puriﬁcation of complexes. The puriﬁed complexes were either treated with
Proteinase K (New England Biolabs) to digest protein residues or with benzonase
nuclease (EMD Millipore) to digest probes and captured RNA and release RNA-
bound protein residues from the streptavidin beads. Proteinase K-treated eluates
were mixed with elution buffer N-lauroylsarcosine-rich (NLS, Sigma-Aldrich)
buffer, heated for 2 min at 95 °C and released from the magnetic beads. Eluted
nucleic acids were captured by magnetic SILANE beads (Invitrogen, Dynabeads
MyOne), treated with DNase I and resuspended in RNase-free water. The isolated
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RNA was reversed transcribed into cDNA and analyzed with RT-qPCR, as
described above.
Polypeptides in the benzonase endonuclease-treated samples were precipitated
by overnight incubation with trichloroacetic acid (Ricca Chemical Company) and
centrifugation (16,000 × g, 10 min, 4 °C). Polypeptides were then digested with
Trypsin (Promega) and Endopeptidase Lys-C (Wako) according to the instructions
of the manufacturers, puriﬁed with HiPPR detergent removal columns (Life
Technologies) and analyzed with liquid chromatography tandem mass
spectrometry (LC/MSMS) on a Thermo Fusion Orbitrap Mass Spectrometer using
1 h LC gradient. Peptides isolated from a total of at least 400 × 106 cells were used
for each experiment. Mass spectrometry analyses were performed in triplicates and
the results were ﬁltered for number and quality of identiﬁed peptides. Proteins with
two or more individual peptides identiﬁed in at least two of the analyzed samples,
and a quality score of ≥30 were considered as putative interactors. The identiﬁed
potential interactors were further ﬁltered on the basis of previously reported RNA-
binding capacity56,57 and were analyzed comparatively to identify putative HOXB-
AS3- and U1-speciﬁc protein interactors.
For the RAP-DNA experiments, the same experimental principles were used for
capturing the targeted transcripts with some modiﬁcations. Cross-linking was
performed with a combination of formaldehyde and DSG treatment, as previously
described58. Biotinylated probes with sequences identical to that of HOXB-AS3
(which were expected to hybridize to the complementary DNA strain of the
HOXB-AS3 gene, but not the HOXB-AS3 transcript) were used as controls. Probes
were hybridized with lysates for 3 h, at 37 °C with intermittent shaking (1100 rpm).
RNA immunoprecipitation and protein co-immunoprecipitation experiments.
RIP experiments and co-immunoprecipitation (co-IP) experiments were conducted
in nuclear lysates according to protocols provided by Abcam (http://www.abcam.
com/epigenetics/rna-immunoprecipitation-rip-protocol). For the RIP experiments
aimed at the validation of the RAP screening, either OCI-AML3 cell lysates and the
corresponding antibodies [i.e., anti-EBP1 (Abcam), anti-NONO (Abcam), anti-
PHB1 (Cell Signalling Technologies), anti-DHX9 (Abcam), anti-MATR3 and anti-
SRSF2 (Abcam)] or 293T cells transfected with a HOXB-AS3 overexpressing vector
and a pcDNA3 vector expressing a FLAG-tagged protein [i.e., PARK7, PCBP1 or
HNRNPC, in which case an anti-FLAG antibody (Sigma-Aldrich) was used] were
analyzed. In both cases, 10 × 106 cells were cross-linked by exposure to UV irra-
diation (8000 J/m2) prior to cell lysis. Cells were then resuspended in 10 ml of lysis
Buffer consisting of 6 ml of water, 2 ml of PBS, and 2 ml of Nuclear Isolation Buffer
(1.28 M sucrose, 40 mM Tris-HCl pH 7.5, 20 mMMgCl2, 4% Triton X-100). Nuclei
were pelleted by centrifugation (2500 × g, 15 min, 4 °C), and were then resuspended
in 1 ml of RIP Buffer (150 mM KCl, 25 mM Tris pH 7.4, 5 mM EDTA, 0.5 mM
DTT, 0.5% NP40 plus RNase and Protease inhibitors). Cell pellets were sonicated
with a microtip sonicator (pulse-sonication at 5W for 10 s followed by a 20-s
interval, repeated for a total of three times) and spun down for 10 min at 16,000 × g
at 4 °C. Supernatants were mixed with magnetic A/G beads (Pierce Biotechnology),
pre-coated with antibodies and incubated overnight at 4 °C, rotating. For the co-IP
experiments antibodies were cross-linked to beads by use of dimethyl pimelimidate
(DMP) according to the instructions provided by Abcam (http://www.abcam.com/
protocols/cross-linking-antibodies-to-beads-protocol). After incubation, beads
were magnetically separated, washed and mixed with either proteinase K-
containing solution (New England Biolabs) for RIP experiments, or with equal
volumes of beta-mercaptoethanol-containing Lamelli buffer for co-IP experiments.
After proteinase K-treatment (incubation for 1 h at 52 °C) samples were mixed
with 1 ml of Trizol reagent. Standard Trizol-based RNA isolation was subsequently
performed. For co-IP experiments, the beads were denatured at 99 °C for 10 min.
Following magnetic removal of beads, the eluates were directly loaded onto SDS-
PAGE gels and separated by electrophoresis.
Chromatin-immunoprecipitation experiments. For chromatin-
immunoprecipitation experiments, antibodies against RNA Polymerase I
(POLR1A, Abcam) and against EBP1 (Abcam) were used. To isolate nucleolar
chromatin we used the experimental approach described by O’Sullivan et al.59. In
brief, cells were cross-linked with formaldehyde (incubation with 0.25% solution
for 10 min) and washed with PBS. After centrifugation at 200 × g for 5 min, cell
pellets were resuspended in 1 ml of high-magnesium buffer (10 mM HEPES Buffer,
0.88M sucrose, 12 mM MgCl2, and 1 mM DTT plus protease inhibitors). Nucleoli
were released by sonication on ice (three bursts of 10 s each at 20W). Nucleoli were
pelleted by centrifugation in a tabletop microcentrifuge (15,000 × g, 10 min, 4 °C),
and the pellets were resuspended in 1 ml of low-magnesium buffer (10 mM HEPES,
0.88M sucrose, 1 mM MgCl2, and 1 mM DTT plus protease inhibitors). Nucleoli
were subject to further sonication on ice (10 s at full power) and pelleted as before.
Isolated nucleoli were resuspended in 0.2 ml of 20/2TE (20 mM Tris, 2 mM EDTA)
plus 1/10 volume of 20% SDS. Following incubation at 37 °C for 15 min, 800 µl of
20/2TE were added, and the solutions were sonicated (three to four bursts of 5 s
each at full power). The resulting sheared nucleolar chromatin was centrifuged in a
microcentrifuge (15,000 × g, 10 min, 4 °C), and the nucleolar chromatin super-
natant was used immediately in ChIP assays.
POLR1A or EBP1 antibodies were incubated with magnetic agarose A/G beads
for 1 h at room temperature and washed twice with PBS. Agarose beads were
blocked by incubation in 2% BSA and salmon sperm containing solution. Cell
lysates were pre-cleaned with blocked agarose beads. Antibody-coated beads were
incubated overnight with nucleolar lysates. Chromatin immunoprecipitates were
puriﬁed with phenol:chloroform:isoamyl alcohol (25:24:1) according to the
instructions of the manufacturer (Thermo Scientiﬁc) and analyzed with the Simple
Chip 28S rDNA assay (Cell Signaling Technology).
Western blots. For the detection of proteins, cells were lysed with 50–100 µl of
RIPA buffer (Pierce Biotechnology), supplemented with proteinase and phospha-
tase inhibitors (EMD Millipore). Samples were incubated on ice for 30 min and
were intermittently vortexed and sonicated (three bursts of 10 s at 3W). Lysates
were cleared by centrifugation in a tabletop centrifuge (16,000 × g, 10 min, 4 °C).
Supernatants were transferred to fresh tubes and protein concentration was mea-
sured by means of Bradford protein assays.
Equal amounts of proteins were mixed with Lamelli Buffer (Bio-Rad)
supplemented with 5% beta-mercaptoethanol (Sigma-Aldrich). Samples were
denatured by incubation at 99 °C for 10 min. Samples were then loaded on sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels and
subsequently weight-separated by electrophoresis. Separated proteins were then
transferred to Nitrocellulose membranes with the Fast-Transfer apparatus and kit
(Bio-Rad). All antibodies used in this study are listed in Supplementary Table 4.
Unless otherwise stated, primary antibodies were used in a 1:1000 and secondary
antibodies in a 1:5000 dilution.
rRNA transcription reporter assays. K-562 cells were concomitantly transfected
with (i) the pRL-TK Renilla Luciferase (0.1 μg), (ii) the pGL3-IRES-Luc or the
pHrD-IRES-Luc (0.9 μg) and (iii) the empty pcDNA3 or the pcDNA3-HOXB-AS3
overexpressing vectors (1.5 μg). Transfected cells were incubated for 72 h in 37 °C/
5% CO2 and were then lysed in lysis buffer (Promega), according to the instruc-
tions of the manufacturer. Luciferase activity was measured using the Dual-Glo
Luciferase Assay kit (Promega) in a luminometer (Glomax Luminometer,
Promega).
De novo protein synthesis assays. To evaluate the effect of HOXB-AS3 KD in de
novo protein synthesis we used an O-proargyl-puromycin (OPP) labeling kit
according to the instructions of the manufacturer (Cayman Chemicals). We
incubated cultured cells in OPP containing medium (2 h for OCI-AML3 cells and
patient blasts, and 45 min for K-562 cells), in order to label newly synthetized
peptides. Cells were then ﬁxed with 10% formalin, washed and conjugated with an
Alexa-Fluor 488 ﬂuorochrome. Cycloheximide-treated samples were used as
negative controls. Samples were analyzed immediately after preparation by ﬂow
cytometry analyses.
Generation of truncated HOXB-AS3 variants. To generate truncated HOXB-AS3
variants, which sequentially lacked ~100 nucleotides compared with the wild-type
transcript, we designed primers (Supplementary Table 1f) and conducted overlap
PCR experiments using Phusion Polymerase according to the instructions of the
manufacturer (New England Biolabs). Amplicons were cloned into TOPO-blunt
end vectors (Invitrogen) and sequenced. Vectors containing validated amplicons
were digested with HindIII and BamHI and cloned into pcDNA3 vectors as
described above.
Biotinylation of wild-type HOXB-AS3 and the truncated HOXB-AS3 variants.
To generate biotinylated HOXB-AS3wt or mutated HOXB-AS3 variants, the
pcDNA3 vectors containing the respective sequences were digested with the ApaI
restriction enzyme (New England Biolabs). Digested vectors were weight-separated
by agarose gel electrophoresis, visualized and puriﬁed from the gel with the Qiagen
gel extraction kit. Puriﬁed vectors were used as template in an overnight T7 RNA
transcriptase-mediated reaction (New England Biolabs), which was conducted in
the presence of biotinylated ribonucleotides (Roche), according to the instructions
of the manufacturer.
Generated biotinylated RNA was puriﬁed with a Trizol extraction and
measured on a Nanodrop device. Equal amounts of biotinylated RNA were mixed
with 100 µl of magnetic streptavidin beads (MyOne Silane). Bead-bound
biotinylated RNA was mixed and allowed to hybridize with nuclear lysate of K-562
cells (lysates of 10 × 106 cells were used per reaction and were incubated for 30 min
at 37 °C). Streptavidin beads were magnetically separated, washed and mixed with
beta-mercaptoethanol-containing buffer. The eluates were denatured by incubation
at 99 °C for 10 min and were then loaded on SDS-PAGE gels.
Mass spectrometry analysis. Samples were digested with trypsin and the peptides
were analyzed using LC/MSMS on a Thermo Scientiﬁc orbitrap Fusion mass
spectrometer equipped with an EASY-Spray™ Sources operated in positive ion
mode. Samples were separated on an easy spray nano column (PepmapTM RSLC,
C18 3 µ 100 A, 75 µm × 150 mm) using a 2D RSLC HPLC system from Thermo
Scientiﬁc. Mobile phase A was 0.1% formic acid in water and acetonitrile (with
0.1% formic acid) was used as mobile phase B. Flow rate was set at 300 nL/min.
MS/MS data were acquired with a spray voltage of 1.7 KV and a capillary tem-
perature of 275 °C is used. The scan sequence of the mass spectrometer was based
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on the preview mode data dependent TopSpeed™ method. To achieve high mass
accuracy MS determination, the full scan was performed at FT mode and the
resolution was set at 120,000. EASY-IC was used for internal mass calibration. The
AGC Target ion number for FT full scan was set at 4 × 105 ions, maximum ion
injection time was set at 50 ms and micro scan number was set at 1. MSn was
performed using ion trap mode to ensure the highest signal intensity of MSn
spectra using both HCD methods (30%). The AGC Target ion number for ion trap
MSn scan was set at 10,000 ions, maximum ion injection time was set at 30 ms and
micro scan number was set at 1. Dynamic exclusion is enabled with a repeat count
of 1 within 60 s and a low mass width and high mass width of 10 ppm. Sequence
information from the MS/MS data were processed by converting the .raw ﬁles into
a merged ﬁle (.mgf) using MS convert (ProteoWizard). The resulting mgf ﬁles were
searched using Mascot Daemon by Matrix Science version 2.3.2 (Boston, MA) and
the database searched against Uniprot Human database (version 12032015). The
mass accuracy of the precursor ions were set to 10 ppm, accidental pick of one 13C
peaks was also included into the search. The fragment mass tolerance was set to 0.5
Da. Considered variable modiﬁcations were oxidation (Met), deamidation (N and
Q), and carbamidomethylation (Cys). Four missed cleavages for the enzyme were
permitted. A decoy database was also searched to determine the false discovery rate
(FDR) and peptides were ﬁltered according to the FDR. The signiﬁcance threshold
was set at p < 0.05 and bold red peptides is required for valid peptide identiﬁcation.
Proteins with <1% FDR as well as a minimal of two signiﬁcant peptides detected
were considered as valid proteins.
Quantiﬁcation of nucleic acid abundancies. Quantiﬁcation of RNA transcripts
measured with RT-qPCR was performed comparatively, based on the differential
threshold cycle (Ct) value method. Ct values of measured transcripts were nor-
malized against Ct values of human GAPDH mRNA, human ACTB mRNA or
murine Gapdh Ct values, which were used as reference. To determine the RNA
abundance of transcripts in subcellular compartments (i.e., cytoplasmic versus
nuclear compartment or polysomal fractions), the Ct values of the measured
transcripts were normalized against the respective Ct values detected in the input
sample and presented as percent of the amount of transcript in the input sample.
For RNA-antisense puriﬁcation (RAP), RNA-immunoprecipitation and
chromatin-immunoprecipitation (ChIP) experiments, abundance of measured
RNA or DNA was analyzed either as percent of the input sample or as fold-
enrichment of the amplicon in the measured eluate, compared with the respective
negative control sample [e.g., for RIP experiments, the normal rabbit IgG anti-
bodies (Millipore Sigma)].
In silico analysis of HOXB-AS3 and rDNA promoter interaction. In order to
further investigate the interaction of the HOXB-AS3 lncRNA with the rDNA
promoter we used an in silico approach. Speciﬁcally, we used the European
Bioinformatics Institute Sequence Aligner Tool (SAT), which is an on-line available
sequence analyzer (https://www.ebi.ac.uk/Tools/psa/). We examined the strength
of interaction between the rDNA promoter and each of the HOXB-AS3 regions that
were deleted in the truncated variants used in the RAP-DNA experiments. The
SAT generated a composite score that was based on the level of complementarity
between the analyzed sequences (also taking into account the effect of the non-
complementary bases). Higher scores were indicative of higher predicted strength
of interaction between examined sequences.
Statistical analyses. For the quantiﬁcation of nucleic acid abundancies in the
RNA-seq data, the Wilcoxon rank sum test was used to compare HOXB-AS3
expression between NPM1-mutated and NPM1 wild-type patients. For RNA-seq
analyses of scramble versus HOXB-AS3 KD-treated samples, the repeated measures
ANOVA test was used to test for differences in gene expression. Likelihood ratio
tests were performed to determine whether each gene showed signiﬁcant differ-
ential expression between scramble and HOXB-AS3 KD treatments. A false dis-
covery rate threshold FDR < 0.05 was used to detect signiﬁcance in differential
expression between scramble and HOXB-AS3 KD samples.
A t-test comparing two independent samples, assuming unequal variances, was
used to compare the means of HOXB-AS3 expression between BM samples from
healthy donors, NPM1mut and NPM1wt AML patients; to compare the means of
Hoxb5os expression in Npm1WT and Npm1cA/+ mice; and to conduct analyses in
AML xenografts that received short-term treatment with scramble or anti-HOXB-
AS3 gapmers. For all other laboratory experiments, a paired t-test analysis was used
to conduct comparisons. A threshold P-value < 0.05 was used to detect signiﬁcance.
For the long-term in vivo experiment with AML patient xenografts treated with
scramble or anti-HOXB-AS3 gapmers, the estimated probabilities of overall
survival were calculated using the Kaplan–Meier method. The log-rank test was
used to evaluate differences between survival distributions. All analyses of
laboratory experiments were conducted with the GraphPad Prism software.
All data presented in this work (including uncropped and unprocessed scans of
the presented blots) are provided in the Source Data ﬁle that accompanies
the paper.
Data availability
The RNA sequencing datasets that were generated during and/or analyzed during the
current study are available in the GEO repository, under the accession number:
GSE137851. The proteomics datasets that were generated during and/or analyzed during
the current study are available in the ProteomeXchange Consortium via the PRIDE
partner repository with the dataset identiﬁer PXD015520. All reagents (e.g., plasmids,
oligonucleotides, real-time PCR assays) generated during the current study are available
from the corresponding author on reasonable request.
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